243 related articles for article (PubMed ID: 29141790)
1. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
3. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
5. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Harirchian MH; Taalimi A; Siroos B
Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
[TBL] [Abstract][Full Text] [Related]
6. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
8. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
[TBL] [Abstract][Full Text] [Related]
9. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder.
Yoshii F; Moriya Y; Ohnuki T; Ryo M; Takahashi W
Mult Scler Relat Disord; 2016 May; 7():53-7. PubMed ID: 27237757
[TBL] [Abstract][Full Text] [Related]
14. Severe aseptic temporal lobe encephalitis on fingolimod.
Rotstein DL; Bharatha A; Selchen D
Mult Scler Relat Disord; 2018 Jul; 23():4-6. PubMed ID: 29689473
[TBL] [Abstract][Full Text] [Related]
15. [The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod].
Tanaka M
Rinsho Shinkeigaku; 2016 Apr; 56(4):270-2. PubMed ID: 27010095
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
18. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C
Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070
[TBL] [Abstract][Full Text] [Related]
19. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
20. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
